Lipella Pharmaceuticals Inc. Common Stock (LIPO) — Cash Flow-to-Debt Ratio
Lipella Pharmaceuticals Inc. Common Stock (LIPO) has a Cash Flow-to-Debt Ratio of -2734.54x as of September 2025, meaning its operating cash flow of $-2.36 Billion could theoretically repay -2735% of its total liabilities ($862.22K) in one year. See how liquid is Lipella Pharmaceuticals Inc. Common Stoc's working capital to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Lipella Pharmaceuticals Inc. Common Stock Cash Flow-to-Debt Ratio (2019–2024)
Historical debt coverage capacity for Lipella Pharmaceuticals Inc. Common Stock across 6 annual periods. Also explore LIPO shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Lipella Pharmaceuticals Inc. Common Stock (2019–2024)
Year-by-year debt coverage analysis for Lipella Pharmaceuticals Inc. Common Stock. For market capitalisation and broader financial context, see market cap of Lipella Pharmaceuticals Inc. Common Stoc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -5.24x | $-3.95 Million | $754.42K | ▲ +28.1% |
| 2023 | -7.28x | $-3.15 Million | $432.73K | ▼ -406.7% |
| 2022 | -1.44x | $-1.83 Million | $1.27 Million | ▲ +14.4% |
| 2021 | -1.68x | $-989.27K | $589.34K | ▼ -2788.3% |
| 2020 | -0.06x | $-28.58K | $491.70K | ▲ +64.7% |
| 2019 | -0.16x | $-39.12K | $237.26K | — |